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Abstract 
Background: In this study, we aim to evaluate the balance of interleukin (IL)‑33 and its soluble receptor sST2 in 
patients with aplastic anemia (AA).
Methods: Plasma IL‑33, IL‑17 and sST2 levels were measured in patients with active AA (n = 31), AA in remission 
(n = 29) and in healthy subjects (n = 30), using enzyme linked immunosorbent assays (ELISAs).
Results: The results showed that sST2 and IL‑17 levels were significantly elevated in patients with active AA when 
compared to control subjects, but IL‑33 levels were significantly lower in AA patients, which resulted in elevated sST2/
IL‑33 ratios in patients with active disease. During remission stages, the levels of these cytokines were comparable to 
those of healthy controls.
Conclusions: The elevated levels of sST2/IL‑33 in the plasma during active stages of the disease suggest a possible 
role in the pathogenesis and course of AA.
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Background
Acquired aplastic anemia (AA) is primarily considered an 
immune-mediated bone marrow failure syndrome, which 
differs from the other conditions associated with inher-
ited mechanisms [1]. Environmental exposure to, for 
example, drugs, viruses, and chemical and physical tox-
ins, is thought to trigger an aberrant immune response in 
some patients, but most cases are classified as idiopathic 
immune-mediated AA. Aberrant immunity, including 
abnormal immune cells and molecules, contributes to the 
development of acquired AA [2, 3]. It has become evi-
dent that T helper 1 (Th1) and Th2 cells have pathogenic 
importance in AA; activated antigen-presenting cells 
(APCs), particularly dendritic cells (DCs), may promote 
polarization to Th1 cells and activate cytotoxic T lympho-
cytes (CTLs). A variety of immune molecules, including 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) 
and interleukins (ILs) produced by DCs, T lymphocytes 
and stromal cells, comprise a cytokine network for the 
destruction of hematopoietic stem cells [3–6].
Interleukin (IL)-33 (or IL-1F11) is the most recently 
discovered member of the IL-1 cytokine family, which 
was identified as a ligand for the T1/ST2 receptor (ST2; 
also called ST2 L, IL-33R, or IL-1RL1) [7]. Like IL-1, 
IL-33 appears to act as a dual function cytokine with 
both nuclear and extracellular effects [8]. The extracellu-
lar effects of IL-33 are mediated by binding to ST2 with 
subsequent recruitment of IL-1R accessory protein (IL-
1RAcP), leading to the activation of NF-kB and MAPK 
pathways and signaling similar to IL-1. Like other mem-
bers of the IL-1 receptor family, ST2 also exists in a solu-
ble form (sST2), generated by alternative mRNA splicing, 
which acts as a decoy receptor to inhibit IL-33 signaling 
[7]. Over the last several years, several studies have sug-
gested that IL-33 and sST2 are involved in immune dis-
eases such as systemic lupus erythematosus and atopic 
dermatitis [8–10].
IL-17 can be produced by Th17 cells, as well as some 
other immune cells such as mast cells, neutrophils and 
macros. It is associated with autoimmune disease, infec-
tion disease and is treated as a therapeutic target in 
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recent years [11–13]. However, data’s come from differ-
ent research groups were controversial about the expres-
sion of IL-17 between AA patients and normal controls 
[14–16]. Here we further investigate the expression of 
IL-17, IL-33 and sST2 in patients with acquired AA.
In the present study, we hypothesized that the imbal-
ance of IL-33 and sST2 may play an important role in 
acquired AA. Expression levels of IL-17, IL-33 and sST2 
were measured in the serum of 31 newly diagnosed 
patients with active AA, 29 AA patients in remission and 
30 healthy volunteers to investigate the possible role that 
IL-33 and sST2 play in AA.
Methods
Patients and controls
Thirty-one newly diagnosed AA patients (19 females and 
11 males; age range, 16–61 years; median age, 27 years) 
were enrolled in this study. None of these patients 
had been transfused or treated by immunosuppres-
sive therapy prior to sampling. Out of the 31 patients, 
10 patients were diagnosed with severe AA (SAA) and 
21 patients with moderate AA (MAA) according to the 
criteria described by Camitta et al. [17]. Marrow cytoge-
netics were normal in all cases, and Fanconi anemia was 
excluded in children and adolescents based on family 
history and the presence of typical physical characteris-
tics. Patients complicated with diabetes, hypertension, 
cardiovascular diseases, pregnancy, active infection, or 
connective tissue diseases, such as systemic lupus ery-
thematosus, were excluded. Twenty-nine AA patients 
(15 females and 14 males, age range 15–54 years, median 
38  years) were in remission. All of the patients met the 
diagnostic criteria of AA by bone marrow biopsy and 
peripheral blood counts, as recommended by the Inter-
national Study of Aplastic Anemia and Agranulocytosis 
[18]. Thirty healthy controls were included (18 females 
and 12 males; age range, 15–62 years; median, 34 years). 
Enrollment took place between July 2012 and January 
2014 in the Linzi District People’s Hospital and Shandong 
Provincial Hospital Affiliated with Shandong Univer-
sity. Our research was approved by the Medical Ethical 
Committee of the Linzi District People’s Hospital and 
Shandong Provincial Hospital Affiliated with Shandong 
University. An informed consent document was obtained 
from each participant.
Plasma preparation
Peripheral blood was collected into heparin-anticoag-
ulant vacutainer tubes. Plasma was obtained from all 
subjects by centrifugation and stored at −80 °C for deter-
mination of cytokines. Mononuclear cells were isolated 
from heparinized blood by gradient centrifugation on 
Ficoll-Paque (Pharmacia Diagnostics, Uppsala, Sweden).
IL‑33, IL‑17 and sST2 enzyme‑linked immunosorbent assay 
(ELISA)
Plasma IL-33, IL-17 and sST2 were measured using com-
mercial enzyme-linked immunosorbent assay (ELISA) 
kits according to the manufacturer (eBioscience and 
R&D, respectively) instructions. The lower detection lim-
its of the kits for IL-33, IL-17 and sST2 were 7.8, 0.5 and 
31.3 pg/ml, respectively. All samples were repeated three 
times.
Statistical analysis
Data were expressed as the mean ± SD. Statistical signifi-
cance was determined by one-way ANOVA using SPSS 
Windows version 13.0. A probability value P < 0.05 was 
considered statistically significant.
Results
Plasma concentrations of IL‑33 and sST2 in ITP and controls
As shown in Fig. 1a, plasma concentrations of IL-33 in AA 
patients with active disease were found to be significantly 
Fig. 1 Plasma expression of IL‑33 and sST2 in AA and controls. Plasma concentrations of IL‑33 in AA patients with active disease (22.7 ± 13.7 pg/ml) 
were found to be significantly lower than those of healthy controls (45.8 ± 24.6 pg/ml, P < 0.01) and AA patients in remission (36.8 ± 29.5 pg/ml, P 
< 0.01) (a). Plasma sST2 levels of AA patients with active disease (1370.1 ± 530.3 pg/ml) were significantly higher compared with healthy controls 
(903.7 ± 329.3 pg/ml, P < 0.01) and patients in remission (1331.8 ± 454.3 pg/ml, P < 0.01) (b)
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lower than those of healthy controls (22.7  ±  13.7 vs. 
45.8  ±  24.6  pg/ml, P  <  0.01). Plasma sST2 levels of AA 
patients with active disease were significantly higher 
compared with healthy controls (1370.1  ±  530.3 vs. 
903.7 ± 329.3 pg/ml, P < 0.01; Fig. 1b). Active AA patients 
had significantly lower IL-33 and significantly higher sST2 
plasma levels than AA patients in remission (22.6  ±  13.4 
vs. 36.8  ±  29.5  pg/ml, P  <  0.01 and 1370.1  ±  530.3 vs. 
1331.8 ± 454.3 pg/ml, P < 0.01, respectively). However, no 
significant difference was found in plasma levels of IL-33 and 
sST2 between AA patients in remission and healthy controls.
The ratio of sST2/IL‑33 in normal control patients, patients 
with active disease and patients in remission
The IL-33 plasma levels of AA patients with active disease 
were significantly lower than the normal controls, and 
those patients had significant higher sST2 plasma levels 
than the control group. The ratio of sST2/IL-33 in patients 
with active disease was significantly higher the ratio in the 
normal and remission groups (P  <  0.01), but there was 
no significant difference in the sST2/IL-33 ratio between 
patients in remission and the normal group (Fig. 2).
Plasma concentration of IL‑17 in ITP and controls
Plasma IL-17 levels were significantly higher in AA 
patients with active disease than in healthy controls 
(215.5  ±  115.5 vs. 144.3  ±  81.6  pg/ml, P  <  0.01). Sig-
nificantly lower IL-17 plasma levels were found in AA 
patients in remission compared with active AA patients 
(160.0 ±  83.1 vs. 215.5 ±  115.5  pg/ml, P  <  0.01). How-
ever, no significant difference in IL-17 plasma level was 
found between AA patients in remission and healthy 
controls (Fig. 3). There was no correlation between IL-17, 
IL-33 or sST2 level or white blood cell, hemoglobin, and 
platelet counts in the individuals examined in the present 
study.
The correlation between IL‑17 with IL‑33 or sST2 in active 
AA patients
Spearman correlation analysis was used to evaluate 
whether IL-17 expression was correlated with IL-33 
or sST2. As shown in Fig.  4, there was no correlation 
between IL-17 and IL-33 (r2  =  −0.0139, P  =  0.5275; 
N =  31; Fig.  4a) expression or between IL-17 and sST2 
(r2 = −0.0445, P = 0.2544; N = 31; Fig. 4b) expression in 
active AA patients.
Discussion
Patients with active AA disease demonstrated decreased 
levels of IL-33 expression, while the levels of sST2 in 
patients were comparable upregulate to the levels of 
healthy controls. And IL-17 was higher in AA patients 
with active disease. There was no correlation between 
IL-17 and IL-33 expression.
AA is a rare, potentially life-threatening failure of 
hematopoiesis characterized by pancytopenia and bone-
marrow aplasia; AA was originally thought to result from 
a direct toxic effect on hematopoietic stem cells that led 
to a decrease in their numbers. Increased monocyte-
derived DCs (DC1) shifted from the stable form to an 
active one and promoted Th0 cells to polarize into Th1 
cells. The alterations in Th1 lymphocyte function and 
cytokines have been intensively investigated as surro-
gates of AA and as possible candidates of an index for 
diagnosis and prognosis [18, 19].
IL-33 is a pro-inflammatory cytokine belonging to the 
IL-1 family, though its biology presents some differences 
from that of IL-1b. The IL-33 pathway plays a major role 
in immune and inflammatory responses by inducing 
Th2 immune responses [20, 21]. Aberrant IL-33 expres-
sion in patients with autoimmune disorders suggests the 
participation of this inflammatory cytokine in the initia-
tion and progression of diseases including asthma [22], 
Fig. 2 The ratio of sST2/IL‑33 in normal control and AA patients. 
#P < 0.05, active AA vs controls. *P < 0.05, active AA vs AA in remission
Fig. 3 Plasma expression of IL‑17 in AA and controls. #P < 0.05, active 
AA vs controls. *P < 0.05, active AA vs AA in remission
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systemic lupus erythematosus and inflammatory arthri-
tis [23]. Because abnormal expression of IL-33 may lead 
to the autoimmune disease mentioned above, target-
ing IL-33 is likely to provide potential opportunities for 
the treatment of this disorder. The observed reduction 
in IL-33 levels in AA patients was more obvious than in 
AA patients in remission, thereby implying that reduced 
IL-33 expression may lead to more intensive T cell accu-
mulation. Therefore, up-regulating expression of IL-33 in 
AA patients may also represent a therapeutic approach 
against AA.
Suppression of tumorigenicity 2 (ST2) is a member 
of the IL-1 receptor (IL-1R) family that plays a major 
role in immune and inflammatory responses. Alterna-
tive promoter activation and splicing produces both a 
membrane-bound protein (ST2 L) and a soluble form 
(sST2). The transmembrane form of ST2 is selectively 
expressed on Th2- but not Th1-type T cells, and binding 
of its ligand, IL-33, induces Th2 immune responses. In 
contrast, the soluble form of ST2 acts as a decoy recep-
tor by sequestering IL-33 [24]. The IL-33/ST2 pathway 
has important immunomodulatory effects [20]. Tajima S 
found that ST2 protein increased in the serum, reflecting 
severity in the inflammatory process and Th2 immune 
response in the IPF lung [25]. Martínez et  al. reported 
that sST2 is increased in aorta from obese rats, and in 
addition is inducing vascular fibrosis, suggesting that 
sST2 could participate in the remodeling observed in 
obesity [26]. In our present study, AA patients had a rela-
tively increased sST2 level compared to controls. sST2 
may act not only as a decoy receptor by binding IL-33 
and preventing ST2L signaling, but also exerts its direct 
effects modulating immune responses in AA. Further 
understanding of the molecular mechanisms by which 
sST2 regulates aberrant immunity may lead to novel tar-
geted therapies for AA.
IL-17, which can be secreted by Th17 cells, was treated 
as a therapeutic target in some autoimmune disease 
[27], which promote secretion of multiple inflammation 
factors like TNF-α, IL-1, IL-6 and IL-8. IL-17 can also 
inhibit proliferation of human hematopoietic progenitor 
[28, 29]. Our study confirmed IL-17 expression in plasma 
was upregulated in AA, which in accord with earlier 
research [16]. Recent, evidence supports the idea of IL-33 
as an inductor of immune response by influencing differ-
ent regulatory cell populations expressing its receptor. 
Additionally, it has been shown in experimental autoim-
mune encephalomyelitis that IL-33 is capable of dimin-
ishing the secretion of inflammatory cytokines such as 
IFN-γ (Th1) and IL-17 (Th17) [30]. The decreased levels 
of IL-33 may induce upregulation of IL-17, then regulat-
ing the balance of IL-33 and sST2 in AA patients may 
also recover IL-17 expression.
Our results confirmed a reciprocal pattern in expres-
sion of IL-33 and sST2 in AA; the levels of IL-33 were 
significantly decreased in active AA patients than in con-
trols and patients in remission, while sST2 levels were 
not significantly changed in AA patients. The ratio of 
sST2/IL-33 in patients with active disease was signifi-
cantly increased when compared with that of the nor-
mal groups and AA patients in remission. Regulating the 
balance of IL-33 and sST2 in AA patients may also be a 
therapeutic approach against AA, although further stud-
ies are warranted.
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